Skip to content

Study · Case report or series · n = 2 · 2025

4 results

GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.

Taraschi F, Salgarello M

Aesthetic plastic surgery22 Jan 2025Cited by 8 (Europe PMC)

PMID39843868 (opens in a new tab)DOI10.1007/s00266-025-04703-4 (opens in a new tab)PepBankPUB-39843868
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    After breast surgery following liraglutide use, delayed wound healing occurred; one patient continued treatment perioperatively and the other stopped seven days before surgery.

    In plain wordsAfter breast surgery following liraglutide use, delayed wound healing occurred; one patient continued treatment and the other stopped seven days before surgery.

    Peptide
    Liraglutide
    Outcome
    Not applicableDelayed wound healing
    Study

    n = 2

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both patients experienced delayed wound healing.
    1 context sentence
    Summary · context
    Both underwent breast surgeries (implant exchange with mastopexy and reduction mammoplasty) while using GLP-1 agonists (liraglutide). One patient continued therapy perioperatively, while the other discontinued seven days prior to surgery.
  2. 02HumanCase report or seriesSafety outcome

    After breast surgery following liraglutide use, wound dehiscence occurred; one patient continued treatment perioperatively and the other stopped seven days before surgery.

    In plain wordsAfter breast surgery following liraglutide use, wound opening occurred; one patient continued treatment and the other stopped seven days before surgery.

    Peptide
    Liraglutide
    Outcome
    Not applicableWound dehiscence
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Wound dehiscence followed a characteristic progression involving fat necrosis and secondary healing.
    1 context sentence
    Summary · context
    Both underwent breast surgeries (implant exchange with mastopexy and reduction mammoplasty) while using GLP-1 agonists (liraglutide). One patient continued therapy perioperatively, while the other discontinued seven days prior to surgery.
  3. 03HumanCase report or seriesSafety outcome

    After breast surgery following liraglutide use, fat necrosis occurred; one patient continued treatment perioperatively and the other stopped seven days before surgery.

    In plain wordsAfter breast surgery following liraglutide use, fat necrosis occurred; one patient continued treatment and the other stopped seven days before surgery.

    Peptide
    Liraglutide
    Outcome
    Not applicableFat necrosis
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Wound dehiscence followed a characteristic progression involving fat necrosis and secondary healing.
    1 context sentence
    Summary · context
    Both underwent breast surgeries (implant exchange with mastopexy and reduction mammoplasty) while using GLP-1 agonists (liraglutide). One patient continued therapy perioperatively, while the other discontinued seven days prior to surgery.
  4. 04HumanCase report or seriesSafety outcome

    After breast surgery following liraglutide use, secondary healing occurred; one patient continued treatment perioperatively and the other stopped seven days before surgery.

    In plain wordsAfter breast surgery following liraglutide use, secondary healing occurred; one patient continued treatment and the other stopped seven days before surgery.

    Peptide
    Liraglutide
    Outcome
    Not applicableSecondary healing
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Wound dehiscence followed a characteristic progression involving fat necrosis and secondary healing.
    1 context sentence
    Summary · context
    Both underwent breast surgeries (implant exchange with mastopexy and reduction mammoplasty) while using GLP-1 agonists (liraglutide). One patient continued therapy perioperatively, while the other discontinued seven days prior to surgery.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.